Mononucleosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(2 intermediate revisions by one other user not shown)
Line 9: Line 9:
*Following intimate contact with infected saliva, the [[EBV|virus]] infects [[B cells]] located in the oropharyngeal epithelium and subsequently spreads to involve the [[lymph nodes]], [[liver]] and [[spleen]].  
*Following intimate contact with infected saliva, the [[EBV|virus]] infects [[B cells]] located in the oropharyngeal epithelium and subsequently spreads to involve the [[lymph nodes]], [[liver]] and [[spleen]].  


*Mononucleosis was so-named because the count of mononuclear leucocytes ([[white blood cells|white blood cells with a one-lobed nucleus]]) rises significantly.  
*Mononucleosis was so-named because the count of mononuclear leucocytes ([[white blood cells]] with a one-lobed nucleus) rises significantly.  
:*There are two main types of mononuclear leucocytes: [[monocyte]]s and [[lymphocyte]]s.  
:*There are two main types of mononuclear leucocytes: [[monocyte]]s and [[lymphocyte]]s.  
:*Mononuclear leucocytes normally account for about 35% of all white blood cells and in patients infected with mononucleosis, this count can rise to 50-70%.  
:*Mononuclear leucocytes normally account for about 35% of all white blood cells and in patients infected with mononucleosis, this count can rise to 50-70%.  
Line 15: Line 15:


*Humoral response: As with many viral infections, such as [[chicken pox]], [[antibody|antibodies]] to the viral antigens are developed with resultant recovery from acute illness.  
*Humoral response: As with many viral infections, such as [[chicken pox]], [[antibody|antibodies]] to the viral antigens are developed with resultant recovery from acute illness.  
:*In addition, these [[antibody|antibodies]] remain in the system for most individuals, creating a lifelong immunity to further infections.<ref>{{cite web |title=Mononucleosis -- Causes |url=http://www.emedicinehealth.com/mononucleosis/page2_em.htm |date=12/7/2007 |publisher=eMedicineHealth |accessdate=2008-03-01}}</ref>
:*In addition, these [[antibody|antibodies]] remain in the system for most individuals, creating a lifelong immunity to further infections.
:*Also, assessment of these specific antibodies forms the basis to diagnose mononucleosis in patients with atypical presentation or in heterophile negative cases.
:*Also, assessment of these specific antibodies forms the basis to diagnose mononucleosis in patients with atypical presentation or in heterophile negative cases.


Line 79: Line 79:


[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
 
[[Category:Pediatrics]]
[[Category:Pediatrics]]
[[Category:Medicine]]
[[Category:Medicine]]

Latest revision as of 18:06, 18 September 2017

Mononucleosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Causes

Differentiating Mononucleosis from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mononucleosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mononucleosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mononucleosis pathophysiology

CDC on Mononucleosis pathophysiology

Mononucleosis pathophysiology in the news

Blogs on Mononucleosis pathophysiology

Directions to Hospitals Treating Mononucleosis

Risk calculators and risk factors for Mononucleosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Epstein-Barr virus, frequently referred to as EBV, is a member of the herpesvirus family that targets oro-pharyngeal epithelium and B cells. Transmission of the EBV through the air or blood does not normally occur. The incubation period, or the time from infection to appearance of symptoms, ranges from 4 to 6 weeks. Persons with infectious mononucleosis may be able to spread the infection to others for a period of weeks. However, no special precautions or isolation procedures are recommended, since the virus is also found frequently in the saliva of healthy people. In fact, many healthy people can carry and spread the virus intermittently for life. These people are usually the primary reservoir for person-to-person transmission. For this reason, transmission of the virus is almost impossible to prevent.

Pathophysiology

  • Following intimate contact with infected saliva, the virus infects B cells located in the oropharyngeal epithelium and subsequently spreads to involve the lymph nodes, liver and spleen.
  • Mononucleosis was so-named because the count of mononuclear leucocytes (white blood cells with a one-lobed nucleus) rises significantly.
  • There are two main types of mononuclear leucocytes: monocytes and lymphocytes.
  • Mononuclear leucocytes normally account for about 35% of all white blood cells and in patients infected with mononucleosis, this count can rise to 50-70%.
  • In addition, the total white blood count may increase to 10,000-20,000 per cubic millimeter.
  • Humoral response: As with many viral infections, such as chicken pox, antibodies to the viral antigens are developed with resultant recovery from acute illness.
  • In addition, these antibodies remain in the system for most individuals, creating a lifelong immunity to further infections.
  • Also, assessment of these specific antibodies forms the basis to diagnose mononucleosis in patients with atypical presentation or in heterophile negative cases.
  • Cellular response:
  • Is required to control the proliferation of infected B cells.
  • This in turn, helps to terminate active EBV infection and also suppress future infections with EBV.
  • Ineffective cellular response results in excessive proliferation of B cells with resultant EBV-associated malignancies such as Burkitt's lymphoma and nasopharyngeal carcinoma.

Transmission

  • Transmission of EBV requires intimate contact with the saliva of an infected person.
  • Typically, the disease is transmitted from asymptomatic individuals through blood or saliva (hence the kissing disease), or by sharing a drink, or sharing eating utensils. The disease is far less contagious than is commonly thought. In rare cases, a person may have a high resistance to infection.
  • Modes of transmission include:
  • Saliva
  • Epstein-Barr virus (EBV) shed for up to 18 months after primary infection
  • Intermittent viral shedding thereafter in asymptomatic sero-positive patients
  • Increased viral shedding in immunocompromised patients
  • Blood transfusion is rare.
  • Individuals in close living arrangements nearly always pass the infection onto each other, although symptoms may not present for months or even years.

Electron Microscopy

Two Epstein-Barr virions
Two Epstein-Barr virions


Microscopic Pathology

Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission. © PEIR, University of Alabama at Birmingham, Department of Pathology



References


Template:WikiDoc Sources